Menu

Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research

The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.

Jan 7, 2018
Jim Daley

ISTOCK, NO_LIMIT_PICTURES

US pharmaceutical corporation Pfizer announced plans this week to abandon research of new drugs to treat Alzheimer’s and Parkinson’s diseases. The decision will result in about 300 layoffs in the company’s neuroscience discovery and early development programs, which are located in Massachusetts and Connecticut, according to a statement emailed to journalists.

“We have made the decision to end our neuroscience discovery and early development efforts and reallocate funding to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” the company says in the statement (via Reuters).

According to Reuters, Pfizer will continue to develop some drugs in its neuroscience pipeline, such as tanezumab, for osteoarthritis-related joint pain and Lyrica (pregabalin), which is used to treat nerve pain associated with fibromyalgia and diabetes. The company also plans to initiate a new venture fund for neuroscience research.

Pfizer is currently part of the Dementia Discovery Fund, which was launched in 2015 to develop new Alzheimer’s treatments. However, some of its attempts to develop new drugs for the conditions have failed. According to Reuters, Pfizer’s partnership with Johnson & Johnson to develop bapineuzumab, a drug to treat patients with mild to moderate Alzheimer’s, ended in disappointment in 2012 after a second round of clinical trials was unsuccessful.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening